Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 3 » Issue 3

Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV

Authors Annabel H Nickol, Nicholas Hart, Nicholas S Hopkinson, Carl-Hugo Hamnegård, John Moxham, et al

Published Date October 2008 Volume 2008:3(3) Pages 453—462

DOI http://dx.doi.org/10.2147/COPD.S2705

Published 12 October 2008

Annabel H Nickol1,2, Nicholas Hart1,3, Nicholas S Hopkinson1, Carl-Hugo Hamnegård4, John Moxham5, Anita Simonds1, Michael I Polkey1

1Respiratory Muscle Laboratory, Royal Brompton Hospital, London, UK; 2Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK; 3The Lane Fox Unit, St Thomas’ Hospital, London, UK; 4Department of Pulmonary Medicine and Clinical Physiology, Sahlgrenska University, Gotenborg, Sweden; 5Respiratory Muscle Laboratory, King’s College London School of Medicine, King’s College Hospital, London, UK

Background: Noninvasive ventilation (NIV) improves gas-exchange and symptoms in selected chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure. We hypothesized NIV reverses respiratory failure by one or all of increased ventilatory response to carbon-dioxide, reduced respiratory muscle fatigue, or improved pulmonary mechanics.

Methods: Nineteen stable COPD patients (forced expiratory volume in one second 35% predicted) were studied at baseline (D0), 5–8 days (D5) and 3 months (3M) after starting NIV.

Results: Ventilator use was 6.2 (3.7) hours per night at D5 and 3.4 (1.6) at 3M (p = 0.12). Mean (SD) daytime arterial carbon-dioxide tension (PaCO2) was reduced from 7.4 (1.2) kPa to 7.0 (1.1) kPa at D5 and 6.5 (1.1) kPa at 3M (p = 0.001). Total lung capacity decreased from 107 (28) % predicted to 103 (28) at D5 and 103 (27) % predicted at 3M (p = 0.035). At D5 there was an increase in the hypercapnic ventilatory response and some volitional measures of inspiratory and expiratory muscle strength, but not isolated diaphragmatic strength whether assessed by volitional or nonvolitional methods.

Conclusion: These findings suggest decreased gas trapping and increased ventilatory sensitivity to CO2 are the principal mechanism underlying improvements in gas-exchange in patients with COPD following NIV. Changes in some volitional but not nonvolitional muscle strength measures may reflect improved patient effort.

Keywords: COPD; hypercapnic respiratory failure; NIV; pulmonary mechanics; ventilatory drive

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Novel stable cytokine delivery system in physiological pH solution: chitosan oligosaccharide/heparin nanoparticles

Wang B, Tan L, Deng D, Lu T, Zhou C, Li Z, Tang Z, Wu Z, Tang H

International Journal of Nanomedicine 2015, 10:3417-3427

Published Date: 8 May 2015

Development of a novel niosomal system for oral delivery of Ginkgo biloba extract

Jin Y, Wen JY, Garg S, Liu D, Zhou YL, Teng LR, Zhang WY

International Journal of Nanomedicine 2013, 8:421-430

Published Date: 24 January 2013

The genetic basis of severe combined immunodeficiency and its variants

Tasher D, Dalal I

The Application of Clinical Genetics 2012, 5:67-80

Published Date: 7 August 2012

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

Khan AA, Paul A, Abbasi S, Prakash S

International Journal of Nanomedicine 2011, 6:1069-1081

Published Date: 24 May 2011

The spectrum of use of rituximab in chronic lymphocytic leukemia

Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, et al

OncoTargets and Therapy 2010, 3:227-246

Published Date: 26 November 2010

Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study

Robert M Shavelle, David R Paculdo, Scott J Kush, David M Mannino, David J Strauss

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:137-148

Published Date: 18 March 2009

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 30 June 2008